Genedata, a Swiss-based provider of enterprise software solutions for biopharmaceutical R&D, announced on Thursday that its Genedata Profiler has been adopted by Switzerland-based biopharmaceutical company Debiopharm as its single point of access to translational research data to expedite its R&D activities and bring life-saving drugs faster to underserved subjects.

Genedata Profiler provides Debiopharm with a single point of access to internal and external data sources including CROs and public databases to improve data discoverability and usability; automated pipelines for high-performance data processing, harmonisation, and merger to transform unstructured high-dimensional multi-modal data into interoperable, analysis-ready data products for comparable cross-study analyses; and an extendable visualisation and statistical toolbox to allow intuitive and self-service data investigation and evaluation for hypothesis testing.

Carolina Haefliger, Debiopharm head of Translational Medicine, said, 'We have been looking for a digital solution that helps us maximise the value of our R&D data to advance our drug development programs. With Genedata Profiler we have found what we have been searching for. By consolidating large amounts of diverse, multi-source data and enabling our teams to utilise those data easily, Genedata Profiler strengthens our innovative potential, ultimately allowing us to bridge the gap between disruptive research and real-world application.'